China Nutraceutical Market Sees Omega-3 and Novel Ingredient Growth Amid Bone Health Dominance

China's nutraceutical market continues to mature, with an in-depth analysis indicating sustained strength in the bone and joint health category. However, industry experts are observing a burgeoning interest in fish oil omega-3 and liver health supplements. This shift aligns with a growing list of novel food ingredients gaining approval for nutraceutical applications and those traditionally recognised as both food and Chinese medicinal herbs, creating significant opportunities for new product development.

Retail market dynamics are also undergoing change. Multinational firm MEBO Group is spearheading the introduction of US supermarket giant Safeway into China, with the first store slated for Shanghai next year. This development is strategic for US nutrition, food, and beverage brands, as MEBO Group has already begun importing Safeway-branded health supplements, such as Open Nature and Signature Care, through its MEBOGO International Trade and Service Sharing Platform, established in 2021.

Innovation within specific ingredient segments is notable, particularly in krill oil. Chinese companies are moving beyond traditional soft gel capsules and single-ingredient formulations. For example, milk powder manufacturer Beingmate is incorporating phospholipid-bound omega-3 into adult milk powder. Other firms are developing multi-ingredient krill oil formulations tailored for specific health objectives, indicating a broader trend towards diversified dosage formats and functional combinations over the past year.

Further scientific advancements are influencing product positioning. A recent randomised controlled trial highlighted that resistant starch intake can aid weight loss in obese individuals by modulating gut microbiota. As resistant starch is naturally found in common foods like legumes, cereals, and wholegrain bread, this research provides a pragmatic, diet-based solution for obesity and metabolic disorders, offering new formulation angles for fibre-based products.

Finally, strategic collaborations are driving new launches in targeted segments. Sinopharm Foreign Trade and Probi AB have partnered to develop a sports nutrition product, Oyfusion (Yue Le Wei), specifically for bone and joint health. This product, featuring Probi's probiotic blend Probi®Osteo, targets active seniors, showcasing a blend of probiotics and established health categories to address specific demographic needs.

What this means for China

Chinese manufacturers and brand owners must actively monitor the accelerating pace of novel food ingredient approvals to maintain competitive advantage in NPD, particularly in omega-3 and liver health. The 2025 arrival of Safeway in Shanghai presents a new, potentially high-volume channel for imported US brands, increasing market competition and possibly compressing margins for domestic brands that do not differentiate. Procurement leads should assess the availability and cost-effectiveness of new ingredients like specific resistant starches and advanced krill oil forms for reformulation. Regulatory teams must ensure strict compliance with new ingredient usage guidelines and retail channel entry requirements. Brand owners should consider joint ventures or co-development strategies, mirroring the Sinopharm-Probi model, to access specialised ingredient technology and market segments.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.